CoChat
Sign Up
Cited by 109Inflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and BiomarkersLung Cancer Research Studies

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis

Zhang, Na, Jiang, Jianjun, Tang, Sihui, Sun, Gengyun·2020·International Immunopharmacology
DOI 10.1016/j.intimp.2020.106677
Open this paper in CoChat — free account

Abstract

Background High neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are associated with poor prognosis in cancer patients treated with Immune checkpoint inhibitors (ICIs). However, whether this relationship exists in non-small cell lung cancer (NSCLC) patients remains unclear. Thus, this meta-analysis was conducted to investigate the prognostic role of NLR and PLR in NSCLC treated with ICIs. Methods Eligible studies that evaluated the value of pre-treatment or post-treatment NLR/PLR in NSCLC patients received ICIs were obtained by searching PubMed, Web of Science, Cochrane Library, and EMBASE. The pooled hazard ratio (HR) and 95% confidence interval (CI) were used to assess the relationship between NLR/PLR and overall survival (OS) and progression-free survival (PFS). Subgroup analysis and publication bias were conducted to investigate heterogeneity. Results 1845 NSCLC patients from 21 studies were included and three ICIs(nivolumab, pembrolizumab, and atezolizumab) were used. Overall, high NLR was associated with poor OS (HR: 2.50, 95% CI:1.79-3.51, P < 0.001) and PFS (HR: 1.77, 95% CI:1.51-2.01, P < 0.001). Subgroup analyses were consistent with the pooled results. Similarly, the pooled results for PLR showed that elevated PLR was related to inferior OS (HR: 1.93, 95% CI: 1.51-2.01, P < 0.001) and PFS (HR: 1.57, 95%CI: 1.30-1.90, P < 0.001). However, the subgroup analysis based on test time indicated that there was no significant correlation between post-treatment PLR and survival outcomes. Conclusion NLR and pre-treatment PLR could serve as prognostic biomarkers in NSCLC patients treated with ICIs. However, the value of post-treatment PLR needs further to be evaluated.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.intimp.2020.106677

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 40

  1. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394
  2. Reck, 2017, Precision diagnosis and treatment for advanced non-small-cell lung cancer, N. Engl. J. Med., 377, 849, 10.1056/NEJMra1703413 · DOI
  3. Assi, 2018, Immune checkpoint inhibitors in advanced non-small cell lung cancer, Cancer, 124, 248, 10.1002/cncr.31105 · DOI
  4. Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 · DOI · Paper page
  5. Prelaj, 2019, Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer, Eur. J. Cancer, 106, 144, 10.1016/j.ejca.2018.11.002 · DOI
  6. Zhang, 2019, Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy, Front Med., 13, 32, 10.1007/s11684-018-0678-0 · DOI
  7. Costantini, 2019, Giroux Leprieur E. plasma biomarkers and immune checkpoint inhibitors in non-small cell lung cancer: new tools for better patient selection?, Cancers (Basel), 11, 10.3390/cancers11091269 · DOI
  8. Havel, 2019, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Nat. Rev. Cancer, 19, 133, 10.1038/s41568-019-0116-x · DOI · Paper page
  9. Guo, 2018, Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: a meta-analysis of results from multivariate analysis, Int. J. Surg., 60, 216, 10.1016/j.ijsu.2018.11.020 · DOI
  10. Zhao, 2016, Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3,720 patients, Int. J. Cancer, 139, 164, 10.1002/ijc.30060 · DOI
  11. Sun, 2018, The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis, Cancer Manag. Res., 10, 6167, 10.2147/CMAR.S171035 · DOI
  12. Xie, 2019, Prognostic value of baseline neutrophil-to-lymphocyte ratio in outcome of immune checkpoint inhibitors, Cancer Invest., 37, 265, 10.1080/07357907.2019.1639057 · DOI
  13. Benedict Sacdalan, 2018, Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis, Oncotargets Therapy, 11, 955, 10.2147/OTT.S153290 · DOI
  14. Jiang, 2019, Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors, Lung Cancer, 130, 76, 10.1016/j.lungcan.2019.02.009 · DOI
  15. Cao, 2018, A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies, Oncoimmunology, 7, 10.1080/2162402X.2018.1507262 · DOI
  16. Ren, 2019, Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB), Onco Targets Ther., 12, 4235, 10.2147/OTT.S199176 · DOI
  17. Pavan, 2019, Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors, Oncologist, 24, 1128, 10.1634/theoncologist.2018-0563 · DOI
  18. Prelaj, 2019, EPSILoN: a prognostic score for immunotherapy in advanced non-small-cell lung cancer: a validation cohort, Cancers (Basel), 11, 10.3390/cancers11121954 · DOI
  19. Möller, 2020, Blood immune cell biomarkers in patient with lung cancer undergoing treatment with checkpoint blockade, J. immunotherapy, 43, 57, 10.1097/CJI.0000000000000297 · DOI
  20. Hasegawa, 2019, Association of high neutrophil-to-lymphocyte ratio with poor outcomes of pembrolizumab therapy in high-PD-L1-expressing non-small cell lung cancer, Anticancer Res., 39, 6851, 10.21873/anticanres.13902 · DOI
  21. Dusselier, 2019, Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers, PLoS ONE, 14, 10.1371/journal.pone.0219060 · DOI
  22. Amaral, 2019, Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors, Ann. Oncol., 30, 10.1093/annonc/mdz027.004 · DOI
  23. Zer, 2018, Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non–small-cell lung cancer, Clin. Lung Cancer., 19, 426, 10.1016/j.cllc.2018.04.008 · DOI
  24. Takeda, 2018, Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer, Thorac. Cancer, 9, 1291, 10.1111/1759-7714.12838 · DOI
  25. Suh, 2018, Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody, Cancer Immunol. Immunother., 67, 459, 10.1007/s00262-017-2092-x · DOI
  26. Shiroyama, 2018, Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer, Cancer Med., 7, 13, 10.1002/cam4.1234 · DOI
  27. Russo, 2018, Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel, J. Cell. Physiol., 233, 6337, 10.1002/jcp.26609 · DOI
  28. Park, 2018, Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab, Clin. Lung Cancer, 19, 280, 10.1016/j.cllc.2017.12.007 · DOI
  29. Fukui, 2019, Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer: a prospective observational study, Clin. Lung Cancer, 20, 208, 10.1016/j.cllc.2018.04.021 · DOI
  30. Facchinetti, 2018, Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab, Immunotherapy, 10, 681, 10.2217/imt-2017-0175 · DOI
  31. Soyano, 2017, Baseline peripheral blood biomarkers associated with clinical outcome of advanced lung cancer in patients treated with anti-PD-1 antibody, J. Clin. Oncol., 35, 5, 10.1200/JCO.2017.35.15_suppl.e20599 · DOI
  32. Rogado, 2017, Are inflammatory markers predictive of nivolumab efficacy in advanced non-small-cell lung cancer (NSCLC)?, J. Thoracic Oncol., 12, S2107
  33. Patil, 2017, Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab, J. Clin. Oncol., 35
  34. Diem, 2017, Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab, Lung Cancer, 111, 176, 10.1016/j.lungcan.2017.07.024 · DOI
  35. Bagley, 2017, Pretreatment neutrophil-to-lymphocyte ratio (NLR) predicts outcomes with nivolumab in non-small cell lung cancer (NSCLC), J. Thoracic Oncol., 12, S1318, 10.1016/j.jtho.2016.11.1864 · DOI
  36. Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001 · DOI · Paper page
  37. Zhang, 2019, Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis, Cancer Med., 8, 1467, 10.1002/cam4.2024 · DOI
  38. Shoji, 2019, Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors, Lung Cancer, 136, 45, 10.1016/j.lungcan.2019.08.006 · DOI
  39. Tan, 2018, Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: a meta-analysis, Thoracic Cancer, 9, 1220, 10.1111/1759-7714.12815 · DOI
  40. Xu, 2019, Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis, Int. Immunopharmacol., 77, 10.1016/j.intimp.2019.105957 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zhang, N., Jiang, J., Tang, S., & Sun, G.
Affiliations
First Affiliated Hospital of Anhui Medical University (CN)
Corresponding author
Sun, Gengyun
ORCID
Venue
International Immunopharmacology
Publisher
Elsevier BV
Published
2020-08
Volume
85
Pages
106677
ISSN
1567-5769 (ISSN-L)
DOI
10.1016/j.intimp.2020.106677
OpenAlex
W3034365591
Cited by
109
References
5
Citations by year
2026: 10 · 2025: 17 · 2024: 19 · 2023: 16 · 2022: 25 · 2021: 22
FWCI
1.69
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • International Immunopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Key Clinical Specialty Discipline Construction Program of China (3101005005025)
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, non-small cell lung cancer, immune checkpoint inhibitors, prognostic factors, overall survival, progression-free survival, nivolumab, pembrolizumab, atezolizumab, inflammatory markers
MeSH terms
Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Blood Cell Count, Blood Platelets, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Lymphocytes, Neutrophils, Prognosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review